LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.99 USD -9.17% Market Closed
Market Cap: 26m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Income from Continuing Operations
-$42m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Income from Continuing Operations
-$17.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
ProQR Therapeutics NV
NASDAQ:PRQR
Income from Continuing Operations
-€23.9m
CAGR 3-Years
25%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Income from Continuing Operations
-$239.5m
CAGR 3-Years
N/A
CAGR 5-Years
-18%
CAGR 10-Years
-19%
argenx SE
XBRU:ARGX
Income from Continuing Operations
-$277m
CAGR 3-Years
20%
CAGR 5-Years
-22%
CAGR 10-Years
-51%
Merus NV
NASDAQ:MRUS
Income from Continuing Operations
-$244.6m
CAGR 3-Years
-45%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
26m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.18 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Income from Continuing Operations?
Income from Continuing Operations
-42m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Income from Continuing Operations amounts to -42m USD.

What is LAVA Therapeutics NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-39%

Over the last year, the Income from Continuing Operations growth was -32%. The average annual Income from Continuing Operations growth rates for LAVA Therapeutics NV have been -39% over the past three years .

Back to Top